Search

Your search keyword '"Debes, Jose"' showing total 518 results
Start Over Author "Debes, Jose"
518 results on '"Debes, Jose"'

2. Contributors

Author

Aby, Elizabeth, primary, Ahuja, Vineet, additional, Alizzi, Mohammed, additional, Amin, Pravin, additional, Amin, Vinay, additional, Anugwom, Chimaobi M., additional, Arab, Juan Pablo, additional, Arrese, Marco, additional, Balderramo, Domingo, additional, Bane, Abate, additional, Pereira, Luciano Beltrão, additional, Boecker, Joerg, additional, Oldhafer, Karl J., additional, Brunetti, Enrico, additional, Cabada, Miguel Mauricio, additional, Cainelli, Francesca, additional, Clemente, Wanessa Trindade, additional, Currie, Bart J., additional, Debes, Jose, additional, Desalegn, Hailemichael, additional, Diaz, Luis Antonio, additional, Eapen, C.E., additional, Eickhoff, Axel, additional, Flanagan, Siobhan M., additional, Ford, James, additional, Goel, Ashish, additional, Gordeuk, Victor R., additional, Gotuzzo, Eduardo, additional, Idalsoaga, Francisco, additional, Ijeoma, Ifeorah M., additional, Kauffman, Carol A., additional, K.C., Mandip, additional, Lake, John, additional, Leventhal, Thomas M., additional, Linder, Kathleen, additional, Manciulli, Tommaso, additional, Martel, Mariana, additional, Mattos, Ângelo Z., additional, Musa, Yusuf, additional, Norton, Robert, additional, Oldhafer, Karl Jürgen, additional, Owoseni, Opeyemi, additional, Pena, Francisco Guilherme Cancela, additional, Pereira, Leila Moreira Beltrão, additional, Poovorawan, Kittiyod, additional, Qi, Xinshun, additional, Roberts, Lewis R., additional, Saichua, Prasert, additional, Seid, Amir Sultan, additional, Sharma, Vishal, additional, Shrestha, Ananta, additional, Singal, Ashwani K., additional, Sivabalan, Pirathaban, additional, de Barros Lima, Leila Maria Soares Tojal, additional, Sonderup, Mark W., additional, Spearman, C. Wendy, additional, Sripa, Banchob, additional, Tappata, Manaswita, additional, Teschke, Rolf, additional, Genderen, Perry J.J. van, additional, Vento, Sandro, additional, Xuan, Tran Dang, additional, and Yousif Sr, Mirghani Abd El Rahman, additional

Published
2025
Full Text
View/download PDF

5. SAT-129 Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma

Author

Diaz, Luis Antonio, Norero, Blanca, Corsi, Oscar, Ayares, Gustavo, Idalsoaga, Francisco, García, Sergio, Vázquez, Valeria, Lacalle, Lucas, Lazo, Mariana, Ferreccio, Catterina, Mendizabal, Manuel, Piñero, Federico, Martinez, Edmundo, Ijeoma, Ifeorah, Louvet, Alexandre, Piano, Salvatore, Cortez-Pinto, Helena, Wong, Vincent Wai-Sun, Kulkarni, Anand, Cotter, Thomas, Brahmania, Mayur, roblero, Juan Pablo, Dirchwolf, Melisa, Pollarsky, Florencia, George, Jacob, Stauber, Rudolf E, Francque, Sven, Guerra, Patricia, Oliveira, Claudia, Araujo, Roberta, Álvares-da-Silva, Mario, Blaise, Nkegoum, Abraldes, Juan G, Zheng, Ming-Hua, Toro, Luis, Restrepo, Juan Carlos, Ramirez, Wagner, Grgurević, Ivica, Infante, Mirtha, Mbendi, Charles, Carrera, Enrique, Kassas, Mohamed El, Mahmoud, Abdelmajeed, Tesfaye, Yonas Gedamu, Tadesse, Sewale Anagaw, Akalu, Tiruwork Fekadu, Desalegn, Hailemichael, Allaire, Manon, Patrizia, Carrieri, Schattenberg, Jörn, Aguyire, Joan, Micah, Eileen Akonobea, Tachi, Kenneth, Cardona, Katherine Emilia Maldonado, Sanchez, Abel, Sánchez, Marco, Björnsson, Einar S, Iavarone, Massimo, Okamoto, Ryuichi, Some, Fatuma, Hellani, Mohammad Fadel, Gonzalez, Veronica Enith Prado, Chávez-Tapia, Norberto Carlos, Méndez-Sánchez, Nahum, Mucumbi, Sheila Constância Mabote, Ugiagbe, Rose Ashinedu, Akande, Kolawole, Nwoko, Chinenye, Ezenkwa, Uchenna Simon, Okoye, Ifeoma Joy, Hamid, Saeed Sadiq, Quezada, Julissa Lombardo, Girala, Marcos, Padilla, P Martin, Diaz-Ferrer, Javier, Tagle, Martin, Kukla, Michał, Odeghe, Emuobor, wemimo, Rasheed mumini, Reis, Daniela, Mozgovoi, Sergei, Ismail, Mona, Koller, Tomas, Spearman, Wendy, Elhassan, Moawia, Stal, Per, Pazi, Swaleh, Ocanit, Anthony, Masson, Steven, Dunn, Winston, Kamath, Patrick S, Singal, Ashwani, Debes, Jose, Reig, María, Loomba, Rohit, Bataller, Ramon, Lazarus, Jeffrey, Arrese, Marco, and Arab, Juan Pablo

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Published
2023

7. Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study.

Author

Aby, Elizabeth S, Moafa, Ghady, Latt, Nyan, Sultan, Mohammad T, Cacioppo, Paula A, Kumar, Sonal, Chung, Raymond T, Bloom, Patricia P, Gustafson, Jenna, Daidone, Michael, Reinus, Zoe, Debes, Jose D, Sandhu, Sunny, Sohal, Aalam, Khalid, Sameeha, Roytman, Marina, Catana, Andreea Maria, Wegermann, Kara, Carr, Rotonya M, Saiman, Yedidya, Kassab, Ihab, Chen, Vincent L, Rabiee, Atoosa, Rosenberg, Carly, Nguyen, Veronica, Gainey, Christina, Zhou, Kali, Chavin, Kenneth, Lizaola-Mayo, Blanca C, Chascsa, David M, Varelas, Lee, Moghe, Akshata, and Dhanasekaran, Renumathy

Subjects
Humans, Liver Diseases, Hospitalization, Adult, Middle Aged, Female, Male, COVID-19, COVID-19 Vaccines, Post-Acute COVID-19 Syndrome, Digestive Diseases, Vaccine Related, Liver Disease, Clinical Research, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being
Abstract

BackgroundCOVID-19 is associated with higher morbidity and mortality in patients with chronic liver diseases (CLDs). However, our understanding of the long-term outcomes of COVID-19 in patients with CLD is limited.MethodsWe conducted a multicenter, observational cohort study of adult patients with CLD who were diagnosed with COVID-19 before May 30, 2020, to determine long-term clinical outcomes. We used a control group of patients with CLD confirmed negative for COVID-19.ResultsWe followed 666 patients with CLD (median age 58 years, 52.8% male) for a median of 384 (interquartile range: 31-462) days. The long-term mortality was 8.1%; with 3.6% experiencing delayed COVID-19-related mortality. Compared to a propensity-matched control group of patients with CLD without COVID-19 (n=1332), patients with CLD with COVID-19 had worse long-term survival [p

Published
2023

9. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge.

Author

Mattos, Ângelo, Debes, Jose, Dhanasekaran, Renu, Benhammou, Jihane, Arrese, Marco, Patrício, André, Zilio, Amanda, and Mattos, Angelo

Subjects
Hepatocarcinogenesis, Hepatocellular carcinoma, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Surveillance
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, and its prevalence increases continuously. As it predisposes to hepatocellular carcinoma both in the presence and in the absence of cirrhosis, it is not surprising that the incidence of NAFLD-related hepatocellular carcinoma would also rise. Some of the mechanisms involved in hepatocarcinogenesis are particular to individuals with fatty liver, and they help explain why liver cancer develops even in patients without cirrhosis. Genetic and immune-mediated mechanisms seem to play an important role in the development of hepatocellular carcinoma in this population. Currently, it is consensual that patients with NAFLD-related cirrhosis should be surveilled with ultrasonography every 6 mo (with or without alpha-fetoprotein), but it is known that they are less likely to follow this recommendation than individuals with other kinds of liver disease. Moreover, the performance of the methods of surveillance are lower in NAFLD than they are in other liver diseases. Furthermore, it is not clear which subgroups of patients without cirrhosis should undergo surveillance. Understanding the mechanisms of hepatocarcinogenesis in NAFLD could hopefully lead to the identification of biomarkers to be used in the surveillance for liver cancer in these individuals. By improving surveillance, tumors could be detected in earlier stages, amenable to curative treatments.

Published
2021

11. Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID‐19): U.S. Multicenter Experience

Author

Rabiee, Atoosa, Sadowski, Brett, Adeniji, Nia, Perumalswami, Ponni V, Nguyen, Veronica, Moghe, Akshata, Latt, Nyan L, Kumar, Sonal, Aloman, Costica, Catana, Andreea M, Bloom, Patricia P, Chavin, Kenneth D, Carr, Rotonya M, Dunn, Winston, Chen, Vincent L, Aby, Elizabeth S, Debes, Jose D, Dhanasekaran, Renumathy, Kim, Donghee, Roytman, Marina, Viveiros, Kathleen, Chan, Walter, Li, Michael, Vogel, Alexander, Wegerman, Kara, Lee, Tzu‐Hao, and Zhou, Kali

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Genetics, Transplantation, Clinical Research, Organ Transplantation, Clinical Trials and Supportive Activities, Prevention, Liver Disease, Digestive Diseases, Oral and gastrointestinal, Good Health and Well Being, Acute Lung Injury, Adult, Aged, Aged, 80 and over, Alanine Transaminase, COVID-19, Cohort Studies, Female, Humans, Immunosuppression Therapy, Liver Transplantation, Logistic Models, Male, Middle Aged, SARS-CoV-2, COLD Consortium, Medical Biochemistry and Metabolomics, Immunology, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background and aimsCoronavirus disease 2019 (COVID-19) is associated with liver injury, but the prevalence and patterns of liver injury in liver transplantation (LT) recipients with COVID-19 are open for study.Approach and resultsWe conducted a multicenter study in the United States of 112 adult LT recipients with COVID-19. Median age was 61 years (interquartile range, 20), 54.5% (n = 61) were male, and 39.3% (n = 44) Hispanic. Mortality rate was 22.3% (n = 25); 72.3% (n = 81) were hospitalized and 26.8% (n = 30) admitted to the intensive care unit (ICU). Analysis of peak values of alanine aminotransferase (ALT) during COVID-19 showed moderate liver injury (ALT 2-5× upper limit of normal [ULN]) in 22.2% (n = 18) and severe liver injury (ALT > 5× ULN) in 12.3% (n = 10). Compared to age- and sex-matched nontransplant patients with chronic liver disease and COVID-19 (n = 375), incidence of acute liver injury was lower in LT recipients (47.5% vs. 34.6%; P = 0.037). Variables associated with liver injury in LT recipients were younger age (P = 0.009; odds ratio [OR], 2.06; 95% confidence interval [CI], 1.20-3.54), Hispanic ethnicity (P = 0.011; OR, 6.01; 95% CI, 1.51-23.9), metabolic syndrome (P = 0.016; OR, 5.87; 95% CI, 1.38-24.99), vasopressor use (P = 0.018; OR, 7.34; 95% CI, 1.39-38.52), and antibiotic use (P = 0.046; OR, 6.93; 95% CI, 1.04-46.26). Reduction in immunosuppression (49.4%) was not associated with liver injury (P = 0.156) or mortality (P = 0.084). Liver injury during COVID-19 was significantly associated with mortality (P = 0.007; OR, 6.91; 95% CI, 1.68-28.48) and ICU admission (P = 0.007; OR, 7.93; 95% CI, 1.75-35.69) in LT recipients.ConclusionsLiver injury is associated with higher mortality and ICU admission in LT recipients with COVID-19. Hence, monitoring liver enzymes closely can help in early identification of patients at risk for adverse outcomes. Reduction of immunosuppression during COVID-19 did not increase risk for mortality or graft failure.

Published
2020

13. SAT-479-YI Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma

Author

Chotiprasidhi, Perapa, primary, Espinoza, Karina Sato, additional, Ma, Jun, additional, Nartey, Yvonne, additional, Awuku, Yaw, additional, Agyei-Nkansah, Adwoa, additional, Afihene, Mary, additional, Duah, Amoako, additional, Bampoh, Sally, additional, Asibey, Shadrack, additional, Ayawin, Joshua, additional, Wang, Jun, additional, Zheng, Yinan, additional, Hou, Lifang, additional, Hawkins, Claudia, additional, Murphy, Robert, additional, Imade, Godwin, additional, Okeke, Edith, additional, Akanmu, Alani, additional, Lesi, Olufunmilayo, additional, Debes, Jose, additional, Roberts, Lewis, additional, Antwi, Samuel, additional, and Wangensteen, Kirk, additional

Published
2024
Full Text
View/download PDF

16. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study

Author

Kim, Donghee, Adeniji, Nia, Latt, Nyann, Kumar, Sonal, Bloom, Patricia P., Aby, Elizabeth S., Perumalswami, Ponni, Roytman, Marina, Li, Michael, Vogel, Alexander S., Catana, Andreea M., Wegermann, Kara, Carr, Rotonya M., Aloman, Costica, Chen, Vincent L., Rabiee, Atoosa, Sadowski, Brett, Nguyen, Veronica, Dunn, Winston, Chavin, Kenneth D., Zhou, Kali, Lizaola-Mayo, Blanca, Moghe, Akshata, Debes, José, Lee, Tzu-Hao, Branch, Andrea D., Viveiros, Kathleen, Chan, Walter, Chascsa, David M., Kwo, Paul, and Dhanasekaran, Renumathy

Published
2021
Full Text
View/download PDF

18. Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans

Author

Fu, Siyu, Karim, Dhamina, Prieto, Jhon, Balderramo, Domingo, Ferrer, Javier Diaz, Mattos, Angelo Z., Arrese, Marco, Carrera, Enrique, Oliveira, Jeffrey, Debes, Jose D., Boonstra, Andre, Fu, Siyu, Karim, Dhamina, Prieto, Jhon, Balderramo, Domingo, Ferrer, Javier Diaz, Mattos, Angelo Z., Arrese, Marco, Carrera, Enrique, Oliveira, Jeffrey, Debes, Jose D., and Boonstra, Andre

Abstract

Introduction and Objectives: Tolloid like protein 1 (TLL1) rs17047200 has been reported to be associated with HCC development and liver fibrosis. However, to our knowledge, no studies have been performed on Latin Americans and comparative differences between TLL1 rs17047200 in HCC patients from Latin America and Europe are undefined. Materials and Methods: Cross-sectional analysis performed on Latin American and European individuals. We analyzed TLL1 rs17047200 on DNA from 1194 individuals, including 420 patients with HCC (86.0 % cirrhotics) and 774 without HCC (65.9 % cirrhotics). Results: TLL1 rs17047200 genotype AT/TT was not associated with HCC development in Latin Americans (OR: 0.699, 95 %CI 0.456-1.072, p = 0.101) or Europeans (OR: 0.736, 95 %CI 0.447-1.211, p = 0.228). TLL1 AT/TT was not correlated with fibrosis stages among metabolic dysfunction-associated steatotic liver disease (MASLD) patients from Latin America (OR: 0.975, 95 %CI 0.496-1.918, p = 0.941). Among Europeans, alcohol-related HCC had lower TLL1 AT/TT frequencies than cirrhosis (18.3 % versus 42.3 %, OR: 0.273, 95 %CI 0.096-0.773, p = 0.015). Conclusions: We found no evidence that the TLL1 rs17047200 AT/TT genotype is a risk factor for HCC development in Latin Americans or Europeans. A larger study integrating ethnic and etiology backgrounds is needed to determine the importance of the TLL1 SNP in HCC development.

Published
2024

22. Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans.

Author

Siyu Fu, Karim, Dhamina, Prieto, Jhon, Balderramo, Domingo, Diaz Ferrer, Javier, Mattos, Angelo Z., Arrese, Marco, Carrera, Enrique, Oliveira, Jeffrey, Debes, Jose D., and Boonstra, Andre

Subjects
HEPATOCELLULAR carcinoma, LATIN Americans, HEPATIC fibrosis, LIVER diseases, EUROPEANS
Abstract

Introduction and Objectives: Tolloid like protein 1 (TLL1) rs17047200 has been reported to be associated with HCC development and liver fibrosis. However, to our knowledge, no studies have been performed on Latin Americans and comparative differences between TLL1 rs17047200 in HCC patients from Latin America and Europe are undefined. Materials and Methods: Cross-sectional analysis was performed on Latin American and European individuals. We analyzed TLL1 rs17047200 on DNA from 1194 individuals, including 420 patients with HCC (86.0 % cirrhotics) and 774 without HCC (65.9 % cirrhotics). Results: TLL1 rs17047200 genotype AT/TT was not associated with HCC development in Latin Americans (OR: 0.699, 95 %CI 0.456-1.072, p = 0.101) or Europeans (OR: 0.736, 95 %CI 0.447-1.211, p = 0.228). TLL1 AT/TT was not correlated with fibrosis stages among metabolic dysfunction-associated steatotic liver disease (MASLD) patients from Latin America (OR: 0.975, 95 %CI 0.496-1.918, p = 0.941). Among Europeans, alcohol-related HCC had lower TLL1 AT/TT frequencies than cirrhosis (18.3 % versus 42.3 %, OR: 0.273, 95 %CI 0.096-0.773, p = 0.015). Conclusions: We found no evidence that the TLL1 rs17047200 AT/TT genotype is a risk factor for HCC development in Latin Americans or Europeans. A larger study integrating ethnic and etiology backgrounds is needed to determine the importance of the TLL1 SNP in HCC development. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Assessment of STAT4 Variants and Risk of Hepatocellular Carcinoma in Latin Americans and Europeans

Author

Ayoub, Alan, primary, Anugwom, Chimaobi M., additional, Prieto, Jhon, additional, Balderramo, Domingo, additional, Ferrer, Javier Diaz, additional, Mattos, Angelo Z., additional, Arrese, Marco, additional, Carrera, Enrique, additional, Groothuismink, Zwier M. A., additional, Oliveira, Jeffrey, additional, Boonstra, Andre, additional, and Debes, Jose D., additional

Published
2023
Full Text
View/download PDF

33. Validation of serum biomarker panels for early HCC detection: results from a large prospective European and Latin American multicenter study

Author

Beudeker, Boris, primary, Fu, Siyu, additional, Balderramo, Domingo, additional, Mattos, Angelo Z., additional, Carrera, Enrique, additional, Diaz-Ferrer, Javier, additional, Prieto, Jhon, additional, Arrese, Marco, additional, Vogel, Arndt, additional, Banales, Jesus Maria, additional, Oliveira, Jeffrey, additional, Grooshuismink, Anthony, additional, Oord, Gertine, additional, De Man, Robert, additional, Debes, Jose, additional, and Boonstra, Andre, additional

Published
2023
Full Text
View/download PDF

34. Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma

Author

Diaz, Luis Antonio, primary, Norero, Blanca, additional, Corsi, Oscar, additional, Ayares, Gustavo, additional, Idalsoaga, Francisco, additional, García, Sergio, additional, Vázquez, Valeria, additional, Lacalle, Lucas, additional, Lazo, Mariana, additional, Ferreccio, Catterina, additional, Mendizabal, Manuel, additional, Piñero, Federico, additional, Martinez, Edmundo, additional, Ijeoma, Ifeorah, additional, Louvet, Alexandre, additional, Piano, Salvatore, additional, Cortez-Pinto, Helena, additional, Wong, Vincent Wai-Sun, additional, Kulkarni, Anand, additional, Cotter, Thomas, additional, Brahmania, Mayur, additional, roblero, Juan Pablo, additional, Dirchwolf, Melisa, additional, Pollarsky, Florencia, additional, George, Jacob, additional, Stauber, Rudolf E., additional, Francque, Sven, additional, Guerra, Patricia, additional, Oliveira, Claudia, additional, Araujo, Roberta, additional, Álvares-da-Silva, Mario, additional, Blaise, Nkegoum, additional, Abraldes, Juan G, additional, Zheng, Ming-Hua, additional, Toro, Luis, additional, Restrepo, Juan Carlos, additional, Ramirez, Wagner, additional, Grgurević, Ivica, additional, Infante, Mirtha, additional, Mbendi, Charles, additional, Carrera, Enrique, additional, El Kassas, Mohamed, additional, Mahmoud, Abdelmajeed, additional, Tesfaye, Yonas Gedamu, additional, Tadesse, Sewale Anagaw, additional, Akalu, Tiruwork Fekadu, additional, Desalegn, Hailemichael, additional, Allaire, Manon, additional, Patrizia, Carrieri, additional, Schattenberg, Jörn, additional, Aguyire, Joan, additional, Micah, Eileen Akonobea, additional, Tachi, Kenneth, additional, Maldonado Cardona, Katherine Emilia, additional, Sanchez, Abel, additional, Sánchez, Marco, additional, Björnsson, Einar S., additional, Iavarone, Massimo, additional, Okamoto, Ryuichi, additional, Some, Fatuma, additional, Hellani, Mohammad Fadel, additional, Prado Gonzalez, Veronica Enith, additional, Chávez-Tapia, Norberto Carlos, additional, Méndez-Sánchez, Nahum, additional, Mabote Mucumbi, Sheila Constância, additional, Ugiagbe, Rose Ashinedu, additional, Akande, Kolawole, additional, Nwoko, Chinenye, additional, Ezenkwa, Uchenna Simon, additional, Okoye, Ifeoma Joy, additional, Hamid, Saeed Sadiq, additional, Quezada, Julissa Lombardo, additional, Girala, Marcos, additional, Padilla, P. Martin, additional, Diaz-Ferrer, Javier, additional, Tagle, Martin, additional, Kukla, Michał, additional, Odeghe, Emuobor, additional, wemimo, Rasheed mumini, additional, Reis, Daniela, additional, Mozgovoi, Sergei, additional, Ismail, Mona, additional, Koller, Tomas, additional, Spearman, Wendy, additional, Elhassan, Moawia, additional, Stal, Per, additional, Pazi, Swaleh, additional, Ocanit, Anthony, additional, Masson, Steven, additional, Dunn, Winston, additional, Kamath, Patrick S., additional, Singal, Ashwani, additional, Debes, Jose, additional, Reig, María, additional, Loomba, Rohit, additional, Bataller, Ramon, additional, Lazarus, Jeffrey, additional, Arrese, Marco, additional, and Arab, Juan Pablo, additional

Published
2023
Full Text
View/download PDF

35. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium

Author

Yang, Ju Dong, Mohamed, Essa A, Aziz, Ashraf O Abdel, Shousha, Hend I, Hashem, Mohamed B, Nabeel, Mohamed M, Abdelmaksoud, Ahmed H, Elbaz, Tamer M, Afihene, Mary Y, Duduyemi, Babatunde M, Ayawin, Joshua P, Gyedu, Adam, Lohouès-Kouacou, Marie-Jeanne, Ndam, Antonin W Ndjitoyap, Moustafa, Ehab F, Hassany, Sahar M, Moussa, Abdelmajeed M, Ugiagbe, Rose A, Omuemu, Casimir E, Anthony, Richard, Palmer, Dennis, Nyanga, Albert F, Malu, Abraham O, Obekpa, Solomon, Abdo, Abdelmounem E, Siddig, Awatif I, Mudawi, Hatim M Y, Okonkwo, Uchenna, Kooffreh-Ada, Mbang, Awuku, Yaw A, Nartey, Yvonne A, Abbew, Elizabeth T, Awuku, Nana A, Otegbayo, Jesse A, Akande, Kolawole O, Desalegn, Hailemichael M, Omonisi, Abidemi E, Ajayi, Akande O, Okeke, Edith N, Duguru, Mary J, Davwar, Pantong M, Okorie, Michael C, Mustapha, Shettima, Debes, Jose D, Ocama, Ponsiano, Lesi, Olufunmilayo A, Odeghe, Emuobor, Bello, Ruth, Onyekwere, Charles, Ekere, Francis, Igetei, Rufina, Mah'moud, Mitchell A, Addissie, Benyam, Ali, Hawa M, Gores, Gregory J, Topazian, Mark D, and Roberts, Lewis R

Published
2017
Full Text
View/download PDF

36. Revaccination for Hepatitis B in Previous Nonresponders Following Hepatitis C Eradication.

Author

Powell, Jesse G, Goble, Spencer R, and Debes, Jose D

Subjects
HEPATITIS B, BOOSTER vaccines, HEPATITIS C, HEPATITIS C virus, HEPATITIS B virus
Abstract

Background Patients with chronic hepatitis C virus (HCV) do not respond to hepatitis B virus (HBV) vaccination as efficiently as the general population. We assessed if revaccination after HCV treatment resulted in improved response. Methods Previous HBV vaccine nonresponders were prospectively recruited for revaccination after HCV eradication. Hepatitis B surface antibody (HBsAb) testing was performed 1 month after series completion. Results Follow-up HBsAb testing was performed in 31 of 34 enrolled patients with 21 (67.7%) reactive results. There were no significant differences in HBsAb reactivity based on age, sex, race, or advanced fibrosis presence. Conclusions HBV vaccine nonresponders should be considered for revaccination following HCV cure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. O-13 SUB-OPTIMAL GLOBAL PUBLIC HEALTH POLICIES AND STRATEGIES TO TACKLE HEPATOCELLULAR CARCINOMA

Author

Díaz, Luis Antonio, Fuentes, Eduardo, Norero, Blanca, Corsi, Oscar, Ayares, Gustavo, Idalsoaga, Francisco, Pizarro, Gonzalo, García, Sergio, Vázquez, Valeria, Lacalle, Lucas, Arnold, Jorge, Lazo, Mariana, Ferreccio, Catterina, Mendizabal, Manuel, Piñero, Federico, Marín, Juan Ignacio, Addissie, Benyam, Ijeoma, Ifeorah, Louvet, Alexandre, Piano, Salvatore, Pinto, Helena Cortez, Wong, Vincent, Kulkarni, Anand V., Cotter, Thomas G., Brahmania, Mayur, Dunn, Winston, Kamath, Patrick S., Singal, Ashwani K., Debes, José, Reig, María, Loomba, Rohit, Bataller, Ramón, Lazarus, Jeffrey V., Arrese, Marco, and Arab, Juan Pablo

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results